BioSpace News Archive

Aptose Biosciences Inc. announced today that the Company effected a reverse stock split on May 24, 2023 at a ratio of 15-to-1 (the “Reverse Stock Split”).

Carisma Therapeutics Inc. today announced that the Company will present at several investor conferences in June 2023.

Chimeric Therapeutics is please to announce that Jennifer Chow, Chief Executive Officer and Managing Director, will present at the Biotechnology Innovation Organization (BIO) International Convention, taking place June 5-8, 2023 at the Boston Convention and Exhibition Center in Boston.

Agenus today announced that its Annual Shareholders Meeting will begin at 10:30 a.m. ET on June 12, 2023 and will be conducted in a virtual format only.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, announced today that it will present at the Jefferies Global Healthcare Conference being held June 7–9, 2023 in New York.

Windtree Therapeutics, Inc., a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, announced it will host a virtual R&D and Investor Day on Wednesday, June 14, 2023 at 1:00 PM ET.

Rani Therapeutics Holdings, Inc. announced that it has expanded its partnership with Celltrion by entering into an agreement for the development of RT-105, an orally administered adalimumab biosimilar.

Amolyt Pharma today announced the initiation of a Phase 1 clinical trial of the Company’s peptide growth hormone receptor antagonist (GHRA), AZP-3813, which is being developed as a potential add-on to somatostatin analogs (SSAs) for the treatment of acromegaly.

NKGen Biotech Inc. (NKGen) today announced a poster presentation of preclinical and Phase I/IIa clinical data by its parent company, NKMax Co., Ltd. (NKMax).

NovelMed Therapeutics, Inc. announced today topline results from First-in-Human Phase I clinical trial of its complement blocker monoclonal anti-Properdin antibody, known as NM3086.